The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.
Lasair O'CallaghanElizabeth ChertavianScott J JohnsonErin FerriesKristina M DeligiannidisPublished in: Journal of medical economics (2024)
This economic model's results suggest that zuranolone is a more cost-effective therapy compared to SSRIs for treating adults with PPD.